No Data
SciSparc Secures FDA Approval to Launch Phase IIB Trial for TS Treatment
SciSparc Secures FDA Green Light to US Launch of Its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
Express News | Scisparc Secures FDA Green Light to US Launch of Its Pivotal Phase Iib Clinical Trial for Breakthrough Tourette Syndrome Treatment
SciSparc Ltd. Proposes Reverse Stock Split
SciSparc Inks Non-binding LOI To Sell Its Entire Ownership Interest In MitoCareX Bio
SciSparc: Amitay Weiss Also Serves as Chairman of Bd of Directors of Purchaser >SPRC
No Data
No Data
